Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun JH, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR. Quan ML, et al. Among authors: teleha ca. J Med Chem. 2005 Mar 24;48(6):1729-44. doi: 10.1021/jm0497949. J Med Chem. 2005. PMID: 15771420
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR. Lam PY, et al. Among authors: teleha ca. J Med Chem. 2003 Oct 9;46(21):4405-18. doi: 10.1021/jm020578e. J Med Chem. 2003. PMID: 14521405
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP. Xue CB, et al. Among authors: teleha ca. J Med Chem. 2001 Aug 2;44(16):2636-60. doi: 10.1021/jm010127e. J Med Chem. 2001. PMID: 11472217
Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.
Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Cain GA, Sun JH, Yan JS, Teleha CA, Fitzgerald LW, McElroy J, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW. Arvanitis AG, et al. Among authors: teleha ca. Bioorg Med Chem Lett. 2003 Jan 6;13(1):125-8. doi: 10.1016/s0960-894x(02)00833-8. Bioorg Med Chem Lett. 2003. PMID: 12467631
MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products.
Duncia JV, Santella JB 3rd, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, Teleha CA, Blom KF, Favata MF, Manos EJ, Daulerio AJ, Stradley DA, Horiuchi K, Copeland RA, Scherle PA, Trzaskos JM, Magolda RL, Trainor GL, Wexler RR, Hobbs FW, Olson RE. Duncia JV, et al. Among authors: teleha ca. Bioorg Med Chem Lett. 1998 Oct 20;8(20):2839-44. doi: 10.1016/s0960-894x(98)00522-8. Bioorg Med Chem Lett. 1998. PMID: 9873633
6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.
Zhang YM, Greco MN, Macielag MJ, Teleha CA, DesJarlais RL, Tang Y, Ho G, Hou C, Chen C, Zhao S, Kauffman J, Camacho R, Qi J, Murray W, Demarest K, Leonard J. Zhang YM, et al. Among authors: teleha ca. J Med Chem. 2018 Nov 21;61(22):10276-10298. doi: 10.1021/acs.jmedchem.8b01467. Epub 2018 Oct 31. J Med Chem. 2018. PMID: 30339387
The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.
Winters MP, Teleha CA, Kang FA, McComsey D, O'Neill JC, Hou C, Kirchner T, Wang P, Johnson D, Sui Z. Winters MP, et al. Among authors: teleha ca. Bioorg Med Chem Lett. 2014 May 1;24(9):2137-40. doi: 10.1016/j.bmcl.2014.03.036. Epub 2014 Mar 22. Bioorg Med Chem Lett. 2014. PMID: 24685539
Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
Zhang Z, Connolly PJ, Lim HK, Pande V, Meerpoel L, Teleha C, Branch JR, Ondrus J, Hickson I, Bush T, Luistro L, Packman K, Bischoff JR, Ibrahim S, Parrett C, Chong Y, Gottardis MM, Bignan G. Zhang Z, et al. J Med Chem. 2021 Jan 28;64(2):909-924. doi: 10.1021/acs.jmedchem.0c01563. Epub 2021 Jan 20. J Med Chem. 2021. PMID: 33470111
Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies.
Kinney WA, Teleha CA, Thompson AS, Newport M, Hansen R, Ballentine S, Ghosh S, Mahan A, Grasa G, Zanotti-Gerosa A, Dingenen J, Schubert C, Zhou Y, Leo GC, McComsey DF, Santulli RJ, Maryanoff BE. Kinney WA, et al. Among authors: teleha ca. J Org Chem. 2008 Mar 21;73(6):2302-10. doi: 10.1021/jo702551t. Epub 2008 Feb 16. J Org Chem. 2008. PMID: 18278942
12 results